CardiaCare, a clinical stage digital therapeutic company developing a non-invasive, neuromodulation wearable for atrial fibrillation treatment, has announced that Ken Nelson has been appointed Chairman of the Board.
Nelson has 20 years’ experience in digital health, medical device, and remote patient monitoring.
He has built sales, marketing and commercialisation teams at Fortune 500 companies as well as startups.
Ofer Halbreich, CEO of CardiaCare, said:
“We are privileged and excited to welcome Ken Nelson to CardiaCare as Chairman of the Board of Directors.
“Ken joins CardiaCare as the company ramps up multiple clinical trials of our revolutionary wearable for atrial fibrillation treatment.
“Ken’s prior experience and success scaling cardiac device companies will be invaluable to us as we create global awareness of CardiaCare’s disruptive innovation and build out the infrastructure towards successful commercialization of our technology.”
Nelson spent just under 10 years in sales and commercial operations leadership roles at Boston Scientific (formerly Guidant) in its Cardiac Rhythm Management division.
Over the past 12 years, he has led commercial sales and marketing efforts and has launched wearable technologies in cardiac digital health and remote patient monitoring.
Ken Nelson, Chairman of the Board, CardiaCare, said:
“I am pleased to join CardiaCare and look forward to working with the management team and the Board, to commercialise the first ever wearable device for closed loop, personalized, atrial fibrillation treatment, powered by artificial intelligence, that can both detect and treat atrial fibrillation non-invasively.
“I’m impressed with the company’s revolutionary technology and the successful engagement with key opinion leaders including Mount Sinai electrophysiologist Dr Vivek Reddy.
“I believe CardiaCare’s innovative solution is poised to advance patient care for the treatment of atrial fibrillation.”
